Drug Trial Radar · NCT05654181
A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult Participants
Last checked: Nov 20, 2026Latest source record: Nov 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Oct 17, 2022
Primary completion
May 3, 2023
Study completion May 3, 2023
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Dec 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is the first clinical study with PF-07328948. The safety, tolerability, and plasma pharmacokinetics and pharmacodynamics of PF-07328948 after administration of escalating, single, oral doses will be evaluated.
Conditions
- Healthy
Interventions
PF-07328948Drug
investigational drug administered orally
PlaceboDrug
Placebo matching active drug administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)Time frame: Day 1-8 per period, along with the 28-35 day post-final dose follow-up
- Number of Participants With Clinical Laboratory Abnormalities Meeting Pre-Defined Categorical Criteria Without Regard to Baseline AbnormalityTime frame: Day 1-8 per period, along with the 28-35 day post-final dose follow-up
- Number of Participants With Vital Signs Abnormalities Meeting Pre-Defined Categorical CriteriaTime frame: Day 1-8 per period, along with the 28-35 day post-final dose follow-up
- Number of Participants With Abnormal Electrocardiogram (ECG) Meeting Pre-Defined Categorical CriteriaTime frame: Day 1-8 per period, along with the 28-35 day post-final dose follow-up
- Change From Baseline in Electrocardiogram (ECG) Parameters (ECG Mean Heart Rate)Time frame: Day 1-8 per period, along with the 28-35 day post-final dose follow-up
- Change From Baseline in ECG Parameters (PR Interval, QRS Duration, and QTcF Interval)Time frame: Day 1-8 per period, along with the 28-35 day post-final dose follow-up
Locations
1 site in 1 country. Site status is shown where the registry gives one.
New Haven Clinical Research Unit
New Haven, Connecticut
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.